Kuwait Pharmaceuticals and Healthcare Market Report Q1 2012

2011-12-28
Published : Dec-2011

BMI View: Kuwait remains regarded as one of the strongest long-term prospects for foreign companies within the Middle East and Africa (MEA) region. Its high per capita spending on drugs, as compared to the regional average, coupled with the import-dependent market, will continue to provide solid commercial opportunities for drug manufacturers. The transformation of its healthcare system from a state-run scheme into a public-private partnership (PPPs) programme should continue to boost this potential, despite the increased government focus on generic drug usage and the negative impact of ongoing patent expirations that will reduce value sales of a number of regionally best-selling medicines.

Kuwait Pharmaceuticals and Healthcare Market Report Q1 2012

Order Now, Contact: + 1 888 391 5441 or [email protected]

Headline Expenditure Projections

.. Pharmaceuticals: KWD182mn (US$637mn) in 2010 to KWD197mn (US$704mn) in 2011; +8.2% in local currency terms and +10.5% in US dollar terms. Forecast slightly down from Q411 due to macroeconomic factors.

.. Healthcare: KWD1.02bn (US$3.57bn) in 2010 to KWD1.17bn (US$4.17bn) in 2011; +14.7% in local currency terms and +17.0% in US dollar terms. Forecast up slightly from Q411 due to new historic data.

.. Medical devices: KWD71mn (US$249mn) in 2010 to KWD76mn (US$273mn) in 2011; +7.2% in local currency terms and +9.4% in US dollar terms. Forecast slightly down from Q411 due to macroeconomic factors.

Business Environment Rating: Kuwait again ranks second out of the now 30 key markets surveyed by our proprietary Business Environment Rating (BER) matrix for the Middle East and Africa (MEA). Its score is, however, 4.6% quarter-on-quarter (q-o-q) lower than in Q411, on account of the small market size, despite the use of new population data that boosted the Country Rewards component of its overall score. Nevertheless, Kuwait’s stable and high value market will continue to provide a major draw for multinationals, especially as patented medicines represent over two-thirds of the market’s value.

Key Trends & Developments

.. India is shortly expected to conclude free trade agreement (FTA) talks with all the member states of the Gulf Cooperation Council (GCC). These talks began officially in 2006, following the 2004 signing of the Framework Agreement on Economic Cooperation, which paved the way for the current negotiations. The FTA should help Indian drugmakers to take a greater market share of the regional generic drug segment, primarily at the expense of Middle Eastern drugmakers.

.. In November 2011, Trade Arabia reported that US-based Marwood Group, a healthcare advisory and financial services firm, inaugurated its operations in Kuwait. The Marwood is operating its local unit in cooperation with Kuwait Life Sciences Company, which is itself a subsidiary of the National Technology Enterprises Company (NTEC). As mandated by the Kuwait Council of Ministers, NTEC’s aim is to enhance private equity and investment inflows into technology projects in the country and wider.

BMI Economic View: We remain optimistic about the prospects for economic growth in Kuwait heading into 2012. We have revised up our forecast for 2011 from 5.3% to 6.1% on the back of higher-thanexpected levels of oil production, while we are sticking to our forecast for real GDP growth of 5.5% in 2012. Moreover, we continue to expect that the Kuwaiti government’s KWD31.0bn Development Plan (DP) will have a positive impact on the Kuwait’s economy. The five-year plan, initiated in February 2010, is an attempt to strengthen the country’s non-hydrocarbon private sector through large investments in infrastructure, health and education. The DP adds to a number of other government policies designed to encourage private sector participation by Kuwaiti citizens, including financial incentives offered to businesses employing Kuwaiti labour and minimum sectoral quotas for the employment of Kuwaiti citizens. However, we now highlight a number of serious downside risks to this forecast, given that global economic woes persist and Kuwait’s political situation looks increasingly unstable.

BMI Political View: Although political unrest in Kuwait has not been on a scale comparable to other countries in the Gulf region, We see a growing possibility that anti-government discontent in Kuwait could translate into increased political instability. Recent actions by the government demonstrate the extent of its concern over underlying political tensions. If controversy over a corruption scandal escalates further over the coming weeks, there is an increasing chance that the emir may accede to opposition demands for dissolution of parliament. This scenario of escalated risk would also hamper the transition of the healthcare system from a welfare state to a system of public-private partnerships (PPPs). Still, given the persistence of small-scale political discontent in the country – coupled with the government’s healthy fiscal position – we are not anticipating any scaling back of public spending over the medium term

SWOT Analysis
Kuwait Pharmaceuticals And Healthcare Industry SWOT
Kuwait Political SWOT
Kuwait Economic SWOT
Kuwait Business Environment SWOT
Pharmaceutical Business Environment Ratings
Table: Middle East And Africa – Regional Pharmaceutical Business Environment Ratings For Q112
Rewards
Risks
Kuwait – Market Summary
Regulatory Regime
Foreign Direct Investment Regulations
Intellectual Property Regime
IP Shortcomings
Pricing Regime
Recent Pricing Regime Developments
Reimbursement Regime
Public Procurement of Medicines
Regional Harmonisation
Free Trade Agreements
Industry Developments
Epidemiology
Communicable Diseases
Non-Communicable Diseases
Healthcare Sector
Healthcare Staff
Primary Care
Secondary Care
Recent Public Health Developments
Healthcare Financing
Healthcare Insurance
Healthcare Insurance Developments
Healthcare Reforms
Research And Development
Clinical Trials
Biotechnology Sector
Medical Devices
Table: Diverse Potential For Product Launches: New Products For 2009
Industry Forecast Scenario
Overall Market Forecast
Table: Pharmaceutical Sales Indicators 2007-2015
Healthcare Market Forecast
Table: Healthcare Expenditure Indicators 2007-2015
Table: Government Healthcare Expenditure Indicators 2007-2015
Table: Private Healthcare Expenditure Indicators 2007-2015
Macroeconomic Forecast
Table: KUWAIT – ECONOMIC ACTIVITY
Prescription Drug Market Forecast
Table: Prescription Drug Sales Indicators 2007-2015
Patented Drug Market Forecast
Table: Patented Drug Market Indicators 2007-2015
Generic Drug Market Forecast
Table: Generic Drug Sales Indicators 2007-2015
OTC Medicine Market Forecast
Table: OTC Medicine Sales Indicators 2007-2015
Medical Device Market Forecast
Table: Medical Devices Sales Indicators 2007-2015
Pharmaceutical Trade Forecast
Table: Exports and Imports Indicators 2007-2015
Other Healthcare Data
Key Risks To BMI Forecasts
Competitive Landscape
Pharmaceutical Sector
Regional Pharmaceutical Sector Developments
Foreign Company Developments
Company Profiles
Local Companies
Kuwait-Saudi Pharmaceutical Industries (KSP)
Advanced Technology Company
Bader Sultan & Bros
Safwan Trading And Contracting Company
Multinationals
Novartis
Sanofi-Aventis
Pfizer
GlaxoSmithKline
Merck & Co
Johnson & Johnson
Country Snapshot: Kuwait Demographic Data
Section 1: Population
Table: Demographic Indicators, 2005-2030
Table: Rural/Urban Breakdown, 2005-2030
Section 2: Education And Healthcare
Table: Education, 2002-2005
Table: Vital Statistics, 2005-2030
Section 3: Labour Market And Spending Power
Table: Employment Indicators, 1997-2006
Table: Consumer Expenditure, 2000-2012
Glossary
BMI Methodology
How We Generate Our Pharmaceutical Industry Forecasts
Pharmaceuticals Business Environment Ratings
Risk/Reward Ratings Methodology
Ratings Overview
Table: Pharmaceutical Business Environment Indicators
Weighting
Table: Weighting Of Components
Filed in: Pharmaceutical, Pharmaceuticals and Healthcare
More Reports
Title Price Buy Now

Ambulatory EHR Market by Delivery Mode (Cloud-based, On-premise), Application (e-Prescribing, PHM, Health Analytics, Practice, Patient & Referral Management), Practice Size (Large, Small-to-Medium, Solo), End User (Independent) – Global Forecast to 2027

“The ambulatory EHR market is projected to grow at a CAGR of 6.1% between 2022 and 2027.” The global ambulatory EHR market is projected to reach USD 5.7 billion in 2022 to USD 7.7 billion by 2027, at a CAGR of 6.1%during the forecast period. Growth in this market is driven by the opportunities provided by the market such as increasing demand for cloud-based ambulatory EHR market, and shift towards patient-centric healthcare delivery. However, the interoperability issues & data security concerns are some of the challenges that are expected to limit the growth of the market to a certain extent during the forecast period. “Cloud-based was the fastest-growing segment in the delivery mode of ambulatory EHR market in 2021” Cloud-based segment is projected to growth at the hi......
$4950

Pharmaceutical Excipients Market by Product (Organic Chemicals (Carbohydrates), Inorganic Chemicals (Calcium Phosphate)), Functionality (Fillers, Binders, Lubricants, Preservatives), Formulation (Tablets, Capsules, Parenteral) – Global Forecast to 2027

“The pharmaceutical excipients market growth can be attributed to factors such as the rising pharmaceuticals market, advancements in functional excipients, and the growing generics market. The rapidly growing biopharmaceuticals sector will also influence market growth..” The pharmaceutical excipients market is projected to reach USD 11.5 Billion by 2027 from USD 8.6 Billion in 2022, at a CAGR of 5.9% during the forecast period.The growth can be attributed to the expanding pharmaceutical industry which has fueled the drug production thereby increasing consumption rate for excipients. Additionally, factors like functional excipients development and upsurge in generics market is also likely to propel market growth. “The fillers & diluents functionality accounted for the larges......
$

Digital Pharmacy Market by Drug (Rx, OTC), Product (Medicine, Personal Care, Vitamins & Supplements, Diabetes, CVD, Oncology), Platform (Apps, Websites), Business Model (Captive, Franchise, Aggregator), Geographic (Urban, Rural) – Global Forecasts to 2027

“Digital Pharmacy market to register a CAGR of 17.0%  during the forecasts period The digital pharmacy market is expected to reach USD 211.9 billion by 2027 from USD 96.5 billion in 2022, at a CAGR of 17.0% during the forecast period. The growth of this market is driven by the growing consumer preference toward buying online medicines during and post COVID-19 pandemic, consolidation in the market and partnerships, and increasing geriatric population. However, patients relying on pharmacists for clinical support and increasing number of illegal pharmacies are expected to restrain the growth of this market during the forecast period. “Over-the-counter (OTC) products segment is estimated  to grow at the highest rate during the forecast period” On the basis  ofdrug type, t......
$4950

Pharmacy Automation Market by Product (Automated Medication Dispensing & Storage Systems, Table-Top Counters, Retrieval Systems, Medication Compounding), End User (Inpatient, Outpatient (Fast-Track Clinics), Retail Pharmacies) – Global Forecast to 2027

The pharmacy automation market is expected to grow at a CAGR of 7.9% in the forecast period. The pharmacy automation market is projected to reach USD 8.2 billion by 2027 from USD 5.6 billion in 2022, at a CAGR of 7.9% during the forecast period. The growth in this market is attributed to the growing need to minimize medication errors, rapid decentralization of pharmacies, and growing focus on automation to reduce labor costs. However, the stringent regulations that delay product launches can inhibit the growth of this market. Based on product, the automated medication dispensing and storage systems segment holds the largest market share in 2021 Based on products, the pharmacy automation market is segmented into automated medication dispensing and storage systems, automated packagi......
$4950

Topical Drug Delivery Market by Type (Semi-solids (Creams, Gels, Lotions), Solids(Suppositories), Liquids(Solutions), Transdermal products), Route(Dermal, Ophthalmic), Facility of Use (Homecare setting, Hospitals, Burn Centres) – Global Forecast to 2027

The topical drug delivery market is expected to grow at a CAGR of 8.9% in the forecast period. The global topical drug delivery market is projected to reach USD 317.8 billion by 2027 from USD 207.4 billion in 2022, at a CAGR of 8.9%. The growth of this market can largely be attributed to the high prevalence of topical prescription therapy for dry eye diseases,  growing focus of pharmaceutical companies on the R&D of smart transdermal drug delivery systems, increase in prevalence of central nervous disorders,  rising preference for non-invasive drug delivery methods. “The semi-solid formulation segment accounted for the largest share of the topical drug delivery market, based on  product in 2021.” Based on products, the topical drug delivery the market is segmented into ......
$4950

Cognition and Memory Enhancement Market by Product & Service (Cognition & Memory-enhancing Drugs, Brain-boosting Nutraceuticals, Cognitive Assessment & Training Solutions), Region (North America, Europe, Asia Pacific, ROW) – Global Forecast to 2026

“Increasing incidence and prevalence of neurological disorders is a key factors driving growth in the cognition and memory enhancement market’’ The global cognition and memory enhancement market is projected to reach USD 38.9 billion by 2026 from USD 23.4 billion in 2021, at a CAGR of 10.7% during the forecast period. Elevating prevalence of neurological disorders, such as dementia, epilepsy, Parkinson’s disease, Huntington’s disease, headache disorders, multiple sclerosis, neuroinfections, stroke, and cerebral palsy, have increased significantly over the years. “By product & service segment, the cognition & memory-enhancing drugs segment has registered fastest growth rate during the forecast period” Based on product & service, the cognition and memory en......
$4950

High Potency APIs/HPAPI Market by Type (Innovative, Generic), Type of Synthesis (Synthetic, Biotech, Biosimilars, mAbs, Vaccines), Manufacturers (Captive, Merchant), Application (Oncology, Hormonal Imbalance, Glaucoma) Region – Global forecast to 2027

The HPAPI market is projected to reach USD 39.6 Billion by 2027 from USD 24.5 billion in 2022, at a CAGR of 10.1% from 2022 to 2027. The market is driven by increasing demand for oncology drugs, growing demand for antibody-drug conjugates and others. “The innovative HPAPIs segment is expected to account for the largest share of the market in 2021” Based on type, the HPAPI market is segmented into innovative and generic. The innovative segment is expected to account for the largest share of the HPAPI market in 2021. The large share can be attributed to the increased R&D investments. “The Synthetic APIs segment to account for the largest share of the market in 2021” Based on type of synthesis, the market is segmented into synthetic and biotech HPAPIs. The synthetic AP......
$4950

Plasma Fractionation Market by Product (Immunoglobulins, Albumin, Protease Inhibitors, von Willebrand Factor, PCC), Application (Neurology, Immunology, Hematology, Rheumatology), End User (Clinical Research, Hospitals & Clinics) – Global Forecast to 2027

“Increased risk of communicable diseases, Rising prevalence of bleeding disorders in global population, Use of Immunoglobulin’s for a range of neurological conditions, including multiple sclerosis, neuropathic pain, and chronic fatigue syndrome is expected to drive the overall growth of the plasma fractionation market.” The global plasma fractionation market size is projected to reach USD 36.7 billion by 2027 from USD 26.5 billion in 2022, at a CAGR of 6.7% during the forecast period. Market growth is driven mainly by factors such as rapid growth of geriatric population, growing prevalence of respiratory disorders such as alpha-1-antitrypsin deficiency (AATD) and emphysema, and use of plasma fractionation products as first-line therapies for a number of bleeding, hematological, an......
$4950

Patient Engagement Solutions Market by Component (Software, Services), Delivery (On-Premise, Cloud), Therapy Area (CVD, Diabetes, Obesity, Fitness), Functionality (E-prescribing, Virtual care), End User (Provider, Payer, Patients) – Global Forecast to 2027

“Patient engagement solutions market to register a CAGR of 10.0% from 2022 to 2027” The patient engagement solutions market is projected to reach USD 27.9 billion by 2027 from USD 17.3 billion in 2022, at a CAGR of 10.0% during the forecast period. The growth of this market is driven by the adoption and changes in government regulations to promote patient-centric care and involve patients throughout the care journey, high demand for patient engagement solutions, and the growing utilization of m- health apps. However, interoperability issues for patient engagement solutions and a dreadth of skilled IT professionals in the healthcare industry are expected to restrain the growth of this market during the forecast period. “Services segment is expected to grow at the highest rate......
$4950

Healthcare Cloud Computing Market by Product (EMR/EHR, VNA, RIS, LIS, PIS), Deployment (Private Cloud, Hybrid Cloud, Public Cloud), Component (Software, Services), Pricing (Spot Pricing), Service (SaaS, IaaS, PaaS), End User – Global Forecasts to 2027

The global Healthcare cloud computing market is projected to reach USD 89.4  billion by 2027 from USD 39.4 billion in 2022, at a CAGR of 17.8%. The factors driving the market are adoption of technologies like telehealth, EHR, big data analytics, IoT, cloud computing, m health, wearlable devices, etc. “The healthcare provider solution was the largest segment in the healthcare cloud computing market in 2021.” The healthcare provider segment accounted for the larger share of 79.2% of the healthcare cloud computing market in 2021. The growing adoption of various health IT solutions such as EHR, e-prescribing, telehealth, mHealth, and others due to COVID-19 is one of the key factors contributing to the growth of this segment. “Among end users, the healthcare providers segment ac......
$4950
We use cookies to deliver the best possible experience on our website.
By continuing to use this site, or closing this box, you consent to our use of cookies. To learn more, visit our Privacy Policy